Mineralys Therapeutics, Inc.

MLYS · Nasdaq · SIC 2834: Pharmaceutical Preparations
65
SEC Filings

Business Summary

Part I Business Overview We are a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. Our product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that we are developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA...

Next Earnings

Q2 FY2026 — expected 2026-09-10

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionMLYSdiscussed_in_filing Cybersecurity
topic_mentionMLYSdiscussed_in_filing Trusted Computing
topic_mentionMLYSdiscussed_in_filing Blockchain & Crypto
topic_mentionMLYSdiscussed_in_filing Regulation
topic_mentionMLYSdiscussed_in_filing Healthcare & Bio
topic_mentionMLYSdiscussed_in_filing Cybersecurity
topic_mentionMLYSdiscussed_in_filing Trusted Computing
topic_mentionMLYSdiscussed_in_filing Blockchain & Crypto
topic_mentionMLYSdiscussed_in_filing Regulation
topic_mentionMLYSdiscussed_in_filing Healthcare & Bio
topic_mentionMLYSdiscussed_in_filing Cybersecurity
topic_mentionMLYSdiscussed_in_filing Trusted Computing
topic_mentionMLYSdiscussed_in_filing Blockchain & Crypto
topic_mentionMLYSdiscussed_in_filing Regulation
topic_mentionMLYSdiscussed_in_filing Healthcare & Bio
topic_mentionMLYSdiscussed_in_filing Cybersecurity
topic_mentionMLYSdiscussed_in_filing Trusted Computing
topic_mentionMLYSdiscussed_in_filing Blockchain & Crypto
topic_mentionMLYSdiscussed_in_filing Regulation
topic_mentionMLYSdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-122025-12-310001933414-26-000056EDGAR77K words
2025-02-122024-12-310001933414-25-000009EDGAR—
2024-03-212023-12-310001628280-24-012358EDGAR—
2023-03-152022-12-310001933414-23-000012EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-102025-09-300001933414-25-000142EDGAR21K words
2025-08-122025-06-300001933414-25-000090EDGAR—
2025-05-122025-03-310001933414-25-000058EDGAR—
2024-11-122024-09-300001933414-24-000057EDGAR—
2024-08-132024-06-300001933414-24-000039EDGAR—
2024-05-092024-03-310001933414-24-000016EDGAR—
2023-11-072023-09-300001933414-23-000087EDGAR—
2023-08-072023-06-300001933414-23-000056EDGAR—
2023-05-152023-03-310001933414-23-000038EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-120001933414-26-000054EDGAR2K words
2026-03-090001933414-26-000048EDGAR—
2026-01-060001933414-26-000002EDGAR—
2025-11-100001933414-25-000139EDGAR—
2025-09-030001933414-25-000120EDGAR—
2025-09-020001933414-25-000107EDGAR—
2025-08-120001933414-25-000088EDGAR—
2025-06-170001933414-25-000070EDGAR—
2025-05-220001933414-25-000064EDGAR—
2025-05-120001933414-25-000057EDGAR—

65 total filings indexed. 42 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001933414
TickerMLYS
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: a1b7e5054ae861dd3d0d83102d370bdd79b04d362d0b1968e9a1529928739cf6
parent: 6f238ac2b0576787be83831867d2cb40c4199e2f924e39cc11ebf2ed60b8dde8
content hash: 4c1ae6925b5179f17459f116e947115d22da1bfd150a2f08d02cf175f590d5d7
signed: 2026-04-13T04:46:17.803Z
sources: 13 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf